Dr John Campbell: Best of 2021

Ivermectin for Prevention and Treatment of COVID-19 Infection 

A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines

https://journals.lww.com/americantherapeutics/Abstract/9000/Ivermectin_for_Prevention_and_Treatment_of.98040.aspx

Background 

The antiparasitic ivermectin, with antiviral and anti-inflammatory properties, has now been tested in numerous clinical trials. A 2018 application for ivermectin use for scabies gives a direct cost of $2.90 for 100 12-mg tablets. Most trials were registered, self-funded, and undertaken by clinicians.

Areas of uncertainty:

We assessed the efficacy of ivermectin treatment in reducing mortality, in secondary outcomes, and in chemoprophylaxis, among people with, or at high risk of, COVID-19 infection.

Data sources:

We searched bibliographic databases up to April 25, 2021. Two review authors sifted for studies, extracted data, and assessed risk of bias. Meta-analyses were conducted and certainty of the evidence was assessed using the GRADE approach and additionally in trial sequential analyses for mortality. Twenty-four randomized controlled trials involving 3406 participants met review inclusion.

• 24 randomized controlled trials 
• N = 3,406 participants 
• Ivermectin reduced risk of death compared with no ivermectin 
• Meta-analysis of 15 trials (n = 2,438)

GRADE approach 

https://training.cochrane.org/grade-approach

• GRADE (Grading of Recommendations, Assessment, Development and Evaluations) 
• GRADE has four levels of evidence, certainty in evidence:

1. very low 
2. low 
3. moderate 
4. high

Results

Certainty in evidence: Moderate 

• Ivermectin reduced risk of death compared with no ivermectin 
• Meta-analysis of 15 trials (n = 2,438)
• Ivermectin verses no ivermectin in hospital patients 
• Ivermectin, 2.3% vs No ivermectin, 7.8% 

Certainty of evidence: Low

• Ivermectin prophylaxis reduced COVID-19 infection 
• 3 trials, n = 738 
• Average reduction 86%

Conclusions

• Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin.
• Using ivermectin early in the clinical course may reduce numbers progressing to severe disease.
• The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.

Related: Dr Tess Lawrie Ivermectin Review

U.K. Nurse/Teacher John Campbell Breaks Down the BBC’s “Reality Check” on Ivermectin by Using Science to Compare IVM to Molnupiravir

Warning: The COVID Jabs Are Administered Incorrectly

In the featured video below, retired nurse lecturer John Campbell, Ph.D., reviews research showing that intravenous injection of mRNA COVID shots can induce acute myo-pericarditis in mice. As it turns out, most health professionals in the U.K. and U.S. are administering the COVID shots incorrectly, thereby raising the risk of serious side effects such as heart inflammation.